A longevity check-up is not about having as many tests as possible or learning from a single report how many years you will live. Its purpose is to identify important health risks that have not yet caused symptoms, measure your current physical and mental capacity and create a personal follow-up plan to increase healthy lifespan.

A good longevity assessment therefore does not set conventional medicine against next-generation ageing biomarkers. Clinically validated measurements such as blood pressure, cholesterol, glucose, kidney function, muscle strength and cardiorespiratory capacity form the foundation; biological age tests may add another perspective in the right person.

In brief: Which tests are meaningful in a longevity check-up?

  • There is no single longevity test package for everyone; age, sex, family history, symptoms and existing diseases change the choice of tests.

  • The most meaningful basic measurements are blood pressure, waist circumference and body composition, glucose regulation, lipids, kidney and liver assessment, and age-appropriate cancer screening.

  • Capacity tests such as muscle strength, balance and VO₂max measure an important area of health that standard blood tests do not reveal.

  • Coronary calcium scoring, advanced hormone tests, continuous glucose monitoring and genetic investigations are meaningful only in selected individuals and when the result will change a decision.

  • Epigenetic tests such as TruAge Complete may report biological age, pace of ageing, 11 organ/system ages and estimated telomere length; however, they do not diagnose disease or replace conventional organ assessments.

What Is a Longevity Check-up? Which Tests Are Truly Meaningful?

What is a longevity check-up?

A longevity check-up is not simply an examination of whether someone is ill today. It seeks to answer three questions together:

  1. Is there an unrecognised disease or important risk today?

  2. What is the current capacity of the muscles, bones, heart and lungs, metabolism and brain?

  3. Which intervention should be undertaken, and how should its benefit be remeasured?

This approach focuses on more than lifespan alone. The main goal is to preserve mobility, mental capacity, independence and quality of life for as long as possible in later years.

“Longevity check-up” is not the name of a single standard package with fixed contents in international guidelines. Programmes offered under the same name can therefore differ considerably. Some provide a comprehensive, risk-focused physician assessment, while others emphasise hundreds of laboratory results, tests with uncertain evidence or a single biological age score.

How does a longevity check-up differ from a standard check-up?

A standard check-up usually investigates existing diseases and common risks. The longevity approach adds three dimensions:

  • Long-term risk: Assesses the likelihood of important future outcomes such as cardiovascular disease, diabetes, kidney disease, fracture and cognitive decline.

  • Functional capacity: Looks beyond blood values to muscle strength, balance, movement and cardiorespiratory capacity.

  • Measurable change: Uses results not as a one-off “good or bad” report, but as a baseline to be remeasured after the plan is implemented.

The two approaches are not alternatives to each other. A good longevity check-up is built on internal medicine and preventive care. New technologies become valuable only when they complement that foundation.

How do we decide whether a test is truly meaningful?

A test appearing technologically advanced does not demonstrate that it benefits health. When evaluating a test, I consider four questions:

  1. Is what it measures clear? Does the test reliably measure the biological characteristic it claims to measure?

  2. Is the result reproducible? Are measurements taken in the same person under similar conditions acceptably consistent?

  3. Is the result associated with a health outcome? Has a relationship with disease, loss of function or mortality risk been demonstrated?

  4. Does the result change a decision? Will a high or low result cause a concrete change in monitoring, lifestyle, medicines or the screening plan?

The last question is the most important. If no decision will change regardless of the result, the test may satisfy curiosity but remain of limited clinical value.

Which basic assessments should a longevity check-up include?

1. Medical and family history

Even the most advanced test cannot replace a well-taken medical history. Existing diseases, medicines and supplements, previous operations, weight changes, sleep, nutrition, movement, smoking and alcohol use should be assessed together.

In family history, the age at onset matters as much as the type of disease. Heart attack or stroke at an early age, sudden death, type 2 diabetes, early osteoporotic fractures, dementia and particular cancer clusters in first-degree relatives may change the testing and screening plan.

2. Examination and basic measurements

Some of the most valuable data in a longevity assessment are quite simple:

  • Blood pressure and pulse measured with correct technique

  • Height, weight, body mass index and waist circumference

  • Weight and waist circumference trends over time

  • Cardiac, lung, thyroid, circulatory and neurological examination findings

  • The necessity, interactions and long-term effects of current medicines

  • Home blood pressure monitoring or orthostatic measurements when needed

A single clinic blood pressure measurement is not always sufficient. Home measurements or 24-hour monitoring in appropriate individuals may show the true blood pressure burden more accurately.

Which blood tests are included in a longevity check-up?

Rather than applying the same broad panel to everyone, basic tests should be supplemented according to individual risk.

Blood cells and organ function

A full blood count provides information about anaemia, some infections and blood cell disorders. Creatinine and calculated eGFR are part of kidney function assessment, while tests such as ALT, AST and GGT contribute to liver assessment. However, normal liver enzymes do not rule out fatty liver, and normal creatinine does not exclude all kidney risks on its own.

The urine albumin-to-creatinine ratio may be important in people with diabetes, hypertension or another risk for kidney disease. KDIGO 2024 recommends assessing kidney health in at-risk individuals using both glomerular filtration rate and urine albumin. [1]

Glucose and metabolic risk

Fasting glucose and HbA1c are basic tools for assessing glucose metabolism. According to the American Diabetes Association’s 2026 standards, asymptomatic adults should first undergo risk assessment; testing should be considered regardless of age in those with overweight or obesity and an additional risk factor. Screening in other adults is recommended to begin no later than age 35. Fasting glucose, HbA1c and the 75-gram oral glucose tolerance test are appropriate screening methods. [2]

Fasting insulin and HOMA-IR may provide additional information in some clinical circumstances, but do not replace standard tests for diagnosing type 2 diabetes. Continuous glucose monitoring is not an obligatory longevity test for everyone with normal glucose either. It may be used for specific purposes, such as suspected prediabetes, symptoms after meals, understanding glucose variability or a structured nutrition intervention.

Cholesterol and cardiovascular risk

Total cholesterol, LDL cholesterol, HDL cholesterol and triglycerides form the basic lipid profile. However, results should be assessed together with age, blood pressure, smoking, diabetes, kidney disease and family history rather than in isolation.

In selected individuals, the following tests may add information:

  • Apolipoprotein B (ApoB): May reflect the number of atherogenic particles more directly; it may be particularly useful with elevated triglycerides, diabetes or metabolic risk.

  • Lipoprotein(a): A risk marker largely determined by genetics. Measuring it at least once in a lifetime may generally be meaningful, particularly with a family history of early heart disease.

  • hs-CRP: May be considered a risk modifier in selected individuals after infection and acute illness have been excluded; it does not diagnose vascular disease on its own.

The 2025 ESC/EAS update considers elevated Lp(a) and, in appropriate individuals, coronary calcium or imaging-detected subclinical atherosclerosis as risk modifiers, particularly at moderate risk or near a treatment decision threshold. [3]

Thyroid, vitamin and hormone tests

TSH may be considered according to symptoms, family history, thyroid disease risk, plans for pregnancy or medicines being used. Ferritin, B12, folate and vitamin D are also meaningful in people with relevant dietary patterns, malabsorption, medicine use, bone health concerns, anaemia or deficiency risk.

However, measuring every vitamin, trace element and hormone in everyone under the name of a “longevity panel” is not necessarily scientific. Testosterone, cortisol, DHEA-S, thyroid hormones and female sex hormones should be requested according to symptoms, age, menstrual or menopausal status, treatments and the clinical question. Trying to bring a single hormone result to a “youthful level” may provide no benefit and may cause harm.

Which tests are genuinely necessary for cardiovascular health?

The first step includes accurate blood pressure measurement, lipids, glucose, smoking status, kidney function and family history. These data can be combined in validated risk models such as SCORE2. SCORE2 was developed to calculate the probability of fatal and non-fatal cardiovascular events over 10 years in specified age groups. [4]

ECG, echocardiography, exercise stress testing, coronary CT and carotid ultrasound are not screening tests to be performed identically in everyone. Symptoms, examination findings, exercise plans, family history and calculated risk determine test selection.

Coronary artery calcium scoring may help decision-making in selected individuals, particularly those at intermediate risk or where the decision to start medication is uncertain. By contrast, routine scanning in a very low-risk young person may generate unnecessary radiation exposure and incidental findings.

Why do DEXA, muscle strength and body composition matter?

Total weight on the scales does not show how much of the body consists of fat, lean tissue or bone. Waist circumference and weight trend are strong starting measurements for most people. DEXA body composition can provide more detailed information on total fat, regional fat distribution and lean tissue in selected individuals.

This information may be particularly useful for:

  • Monitoring muscle loss during weight loss

  • Distinguishing changes in fat and lean tissue during GLP-1 treatment

  • Assessing sarcopenia or frailty risk

  • Considering bone health and body composition together during menopause

  • Measuring the results of an exercise and nutrition programme

Bone mineral density measurement should be planned according to age and fracture risk. The 2025 USPSTF recommendation supports osteoporosis screening with DEXA in women aged 65 and older, and in younger postmenopausal women found to be at increased risk. Decisions in men and those at risk of secondary osteoporosis should follow individual risk and relevant clinical guidelines. [5]

Assessing muscle health solely from muscle quantity on DEXA is also incomplete. Simple performance tests such as grip strength, five chair rises, walking speed and balance provide direct information about everyday capacity. The European Working Group on Sarcopenia considers low muscle strength the main indicator of probable sarcopenia. [6]

Is a VO₂max test necessary for a longevity check-up?

VO₂max refers to the maximum amount of oxygen the body can use during intense exercise and is an important indicator of cardiorespiratory capacity. It can be measured directly through cardiopulmonary exercise testing; some field and device-based tests produce estimates instead.

A large review published in 2024, including more than 20.9 million observations, showed a strong and consistent association between higher cardiorespiratory capacity and lower risks of death and chronic disease. [7]

VO₂max or an appropriate capacity test is therefore valuable, particularly for people planning an exercise programme and wishing to track its results. However, cardiac risk and conditions that may prevent exercise should be reviewed beforehand. Maximal exercise testing may not suit everyone; lower-risk field tests may be selected where needed.

Which tests are used for sleep and brain health?

Alongside sleep duration, assessment should ask about interrupted sleep, snoring, witnessed apnoea, morning headaches and daytime sleepiness. A home sleep test or polysomnography may be considered if sleep apnoea risk is present. Smartwatch sleep data can show trends, but do not provide a diagnosis.

Blood pressure, LDL cholesterol, diabetes, movement, hearing, vision, depression and social connections matter in brain health assessment. Routine brain MRI or an extensive neuropsychological battery is not needed for every healthy person. Targeted assessment is appropriate when there is new forgetfulness, functional decline, neurological findings or a strong family history. In selected situations, a brief cognitive baseline in a healthy adult may help compare later changes; a single score cannot say whether dementia will develop in the future.

How should cancer screening be carried out in a longevity check-up?

Cancer screening is not a broad blood panel of tumour markers. Programmes with demonstrated benefit, appropriate to age, sex, family history and personal risk, should be used.

As of 2026, Türkiye’s population-based programme includes:

  • Mammography every two years for women aged 40–69,

  • HPV-DNA testing every five years for women aged 30–65,

  • Faecal occult blood testing every two years for women and men aged 50–70. [8]

If there is early cancer in the family, a suspected hereditary syndrome or a personal risk, this programme may not be sufficient and screening may begin at a different age. Conversely, requesting CEA, CA 19-9, CA 15-3 and similar tumour markers for general cancer screening in asymptomatic people can lead to false-positive results and unnecessary procedures. Whole-body MRI or CT is not standard longevity screening for everyone at low risk either.

However, in at-risk individuals, whole-body MRI every 2 years, annual chest CT when a lung nodule is present, annual whole-abdomen ultrasound and tests that screen circulating tumour DNA in the blood, known as liquid biopsies, may be effective screening tools.

What is a biological age test?

Chronological age is the time since birth. Biological age is an estimate that attempts to summarise ageing-related changes in the body as a single number or score.

Epigenetic age tests examine DNA methylation patterns, which can influence how genes function without changing the DNA sequence. Machine-learning algorithms relate these patterns to outcomes such as chronological age, organ function, disease or mortality risk to construct different “ageing clocks”.

These clocks do not all measure the same thing. A first-generation clock developed to estimate chronological age should not be interpreted in the same way as a newer clock designed to predict health outcomes or the pace of ageing.

What do biological age tests show?

Biological age tests known as epigenetic clocks provide a comprehensive epigenetic report analysing DNA methylation in a blood sample. Although report versions may be updated over time, the main ageing outputs can be considered under four headings:

Report

What does it aim to describe?

How should it be interpreted?

OMICmAge biological age

Combines protein, metabolite and clinical-feature surrogates calculated from DNA methylation to produce a score associated with overall biological age and health risk.

The difference from chronological age may be viewed as a summary of risk and ageing; it is not, on its own, a disease diagnosis or life expectancy estimate.

DunedinPACE pace of ageing

Estimates the rate of biological change occurring within one calendar year. Approximately 1.0 represents the population reference pace; below 1 is interpreted as slower and above 1 as faster ageing.

It does not provide certainty that “you are ageing by exactly this amount per year right now”; trends in serial measurements on the same platform may be more meaningful.

SYMPHONYAge / Systems Age

Provides age scores for 11 physiological systems: heart, lungs, kidneys, liver, brain, immune system, inflammation, blood, musculoskeletal system, hormones and metabolism.

These are system surrogates derived from blood methylation, not direct organ imaging or functional tests. A high result may generate a hypothesis for assessing the relevant organ through conventional methods.

Estimated telomere length

Estimates leukocyte telomere length from DNA methylation patterns and compares it with the age group.

Does not measure telomeres directly; should not be used to predict individual lifespan, cancer or heart disease.

What does OMICmAge biological age mean?

OMICmAge does not simply try to estimate chronological age from DNA. It brings together epigenetic surrogates associated with proteins, metabolites and routine clinical data in a single DNA methylation test.

In a study published in 2026 in Nature Aging, OMICmAge was associated with existing and future chronic diseases and mortality risk in the Mass General Brigham, TruDiagnostic and Generation Scotland cohorts. [9] This supports the test carrying meaningful biological information at population level. However, a result of 55 in a 50-year-old does not mean that all tissues in the body are exactly 55 years old or that the person will live five fewer years.

How is the DunedinPACE pace of ageing interpreted?

DunedinPACE was developed from the rate of change in 19 indicators of cardiovascular, metabolic, kidney, liver, lung, immune and periodontal systems over 20 years in people born in the same year. This long-term change was then converted into an algorithm that can be estimated from DNA methylation in a single blood sample. [10]

It therefore addresses “In which direction and at what pace are ageing-related system changes progressing?” rather than “How old am I?” Studies have shown associations with disease, disability and mortality risk. However, it is not a perfect speedometer that precisely measures every lifestyle change an individual makes over a short period. The algorithm’s developers also state that, for it to be accepted as a true surrogate endpoint for healthspan, it must be shown that intervention-induced changes in the score also change long-term health outcomes.

How reliable are organ ages?

The 11 organ/system ages in the TruAge report are based on the Systems Age approach offered under the name SYMPHONYAge. A peer-reviewed study published in 2025 developed separate scores for 11 physiological systems from DNA methylation in a single blood sample and reported that these scores could predict related diseases and ageing characteristics more strongly than global age clocks. [11]

This is an important scientific development; however, a result stating “your heart age is 60” does not mean that the heart is definitively 60 years old on imaging or functionally. The test interprets blood methylation patterns using a model trained on clinical and functional characteristics associated with the cardiovascular system.

The appropriate response to a high organ age is therefore not to panic or start treatment immediately. For example:

  • If heart age is high, blood pressure, ApoB/LDL, glucose, family history and overall cardiovascular risk are reviewed.

  • If kidney age is high, creatinine/eGFR, urine albumin and blood pressure are checked.

  • If metabolic age is high, waist circumference, HbA1c, triglycerides, liver health and body composition are assessed.

  • If musculoskeletal age is high, muscle strength, physical performance, DEXA and fracture risk are considered.

  • If brain age is high, vascular risks, sleep, hearing, vision, depression and actual cognitive symptoms are assessed.

In other words, the result may be a hypothesis that guides validated clinical measurements, not a diagnosis that replaces them.

What does a telomere length test tell us?

Telomeres are structures protecting the ends of chromosomes and generally shorten with cell division. However, telomere length is influenced by inherited characteristics, cell type, immune cell distribution, lifelong exposures and the measurement method.

The telomere result in TruAge Complete is an indicator estimated from DNA methylation, rather than a direct telomere measurement by qPCR or Flow-FISH. DNA methylation-based estimates of telomere length have been shown to be associated with age and some health outcomes. [12]

Nevertheless, telomere length on its own only roughly reflects individual ageing pace and does not reliably indicate how long someone will live. A large systematic review showed that telomere length is associated with chronological age, but the relationship is weaker than expected and sensitive to the methods used. [13] The result should not, on its own, justify starting a supplement or treatment claimed to “lengthen telomeres”.

Is a biological age test genuinely necessary?

No; it is not essential for a good longevity check-up. However, it may be useful when used with appropriate expectations.

Situations in which it may be meaningful:

  • Recording a baseline with a multidimensional ageing biomarker

  • Examining whether conventional risks and the biological age score point in the same direction

  • Using an exploratory monitoring indicator within a long-term lifestyle or treatment programme

  • Supporting the person’s participation in, and motivation for, a risk-reduction plan

  • Evaluating the result with a physician alongside other clinical data

Misuses:

  • Calculating lifespan from the result

  • Diagnosing cancer, dementia or heart disease

  • Abandoning cancer screening or risk management because of a “young” result

  • Starting imaging, medication or supplements because of a single “older” organ score

  • Repeating tests frequently to demonstrate changes over a few weeks

Before ageing biomarkers can enter clinical use, they need validation across many areas, including predictive power, reproducibility, generalisability to different populations and response to intervention. A 2024 review in Nature Medicine emphasises that a shared clinical validation standard does not yet exist in this field. [14]

The most appropriate place for biological age testing is therefore alongside, not above clinically validated measurements.

Which tests should not become routine longevity packages?

Without an individual indication, it is generally inappropriate to perform the following investigations in everyone:

  • Broad tumour marker panels

  • Whole-body CT or indiscriminate organ imaging

  • Routine coronary CT, carotid ultrasound or exercise stress testing in asymptomatic low-risk individuals

  • Very broad vitamin, mineral and hormone panels

  • Food IgG or poorly supported “detox” tests whose results do not change clinical decisions

  • Broad hereditary disease panels without a strong personal or family history

  • Continuous glucose monitoring for everyone

  • Frequent biological age and telomere testing across different platforms

A large number of tests increases the likelihood of finding an out-of-range result by chance. This can lead to anxiety, repeat tests, imaging and sometimes unnecessary interventions. The World Health Organization also recommends screening asymptomatic people within programmes with a defined target group, benefit–harm balance and care pathway following a positive result. [15]

How should a good longevity check-up be structured?

First layer: The foundation of every assessment

  • Detailed medical and family history

  • Review of medicines and supplements

  • Examination, blood pressure, pulse, waist circumference and weight trend

  • Basic blood and urine tests appropriate to age and risk

  • Cardiovascular and diabetes risk calculation

  • Checking age- and sex-appropriate cancer screening

  • Assessment of sleep, mental health, nutrition and physical activity

Second layer: Capacity and body composition

  • Muscle strength and physical performance

  • DEXA body composition and bone density in appropriate individuals

  • VO₂max or a safe cardiorespiratory capacity test

  • Balance and movement quality

  • Sleep testing or baseline cognitive assessment when needed

Third layer: Only according to risk or purpose

  • ApoB, Lp(a), hs-CRP

  • Oral glucose tolerance testing or temporary continuous glucose monitoring

  • Coronary artery calcium scoring and targeted imaging

  • Genetic counselling and selected genetic tests

  • Epigenetic biological age tests

This sequence does not mean that advanced tests are worthless. It shows that their value can be interpreted more accurately once the basic clinical data are known.

You can explore how this approach is used in a personal consultation on the longevity assessment process in Bodrum page.

How often should a longevity check-up be performed?

There is no single interval that applies to everyone. A healthy, low-risk individual and someone with newly detected hypertension, prediabetes or rapid weight loss do not require the same follow-up interval.

For many people, the overall health plan can be reviewed annually, but not every test needs repeating every year. Blood pressure and weight may be monitored more frequently, while bone density may be assessed at longer intervals. When treatment begins, lipids, glucose, kidney or liver tests may need earlier review.

There is no evidence-based standard interval for repeating biological age tests. If serial monitoring is intended, the same laboratory and algorithm should be used, the effects of acute illness and short-term fluctuations considered, and enough time allowed for meaningful biological change. In practice, interpreting repeats more frequent than every 6–12 months requires particular care; this interval is not a universal medical rule.

Conclusion: The best longevity check-up is the assessment that leads to the right decisions, not the most tests

The value of a longevity check-up is not measured by the number of pages or tests in the report. A good programme identifies silent risks, measures muscle and cardiopulmonary capacity, completes age-appropriate screening and translates results into an actionable plan.

Next-generation epigenetic tests such as TruAge Complete offer an interesting and increasingly well-supported scientific window through biological age, pace of ageing, organ system ages and estimated telomere length. But this window is not the whole room. A “young” biological age does not make high blood pressure unimportant, and a “high” heart age does not establish a diagnosis of heart disease.

For me, the right sequence is: First measure clinical risks and capacity, then put advanced biomarkers in the right context, and finally translate the results into a concrete health plan.

This article provides general information. It does not replace a personal health assessment, diagnosis or treatment plan. Test selection and interpretation should take into account the person’s age, symptoms, family history and existing diseases.

Frequently asked questions

At what age should a longevity check-up be performed?

There is no single starting age. A family history of early heart disease, diabetes or cancer may require risk assessment at a younger age. In general, recording long-term risks and baseline capacity from the thirties, followed by more structured monitoring after the forties, may be meaningful.

Does a longevity check-up consist only of blood tests?

No. Although blood tests are important, the picture remains incomplete without assessing blood pressure, waist circumference, body composition, muscle strength, cardiorespiratory capacity, sleep, mental health and age-appropriate screening.

Are biological age tests reliable?

Modern epigenetic clocks can generate powerful information associated with disease, loss of function and mortality risk at population level. However, the precision of individual results, agreement between platforms and translation into treatment decisions remain developing areas. Results should therefore be interpreted alongside clinical measurements rather than on their own.

Which ageing results does TruAge Complete provide?

The current basic report provides OMICmAge biological age, DunedinPACE pace of ageing, 11 organ/system ages through SYMPHONYAge and estimated telomere length from DNA methylation. As report contents may be updated over time, the version being used should be checked separately.

If my organ age is high, does that organ have a disease?

No. Organ age is a statistical system score calculated from DNA methylation in blood. It does not diagnose disease. The result may be considered a signal to assess the relevant system more carefully using validated clinical tests.

Does telomere length show how many years I will live?

No. Telomere length is only one part of ageing biology. Genetics, cell type, environmental factors and the measurement method affect the result. Individual lifespan cannot be calculated from a single measurement.

Can biological age be reversed?

Some studies may show changes in particular epigenetic clocks after lifestyle changes or treatments. However, a younger score does not yet prove that organs have become younger to the same extent or that long-term disease risk has definitely fallen. The main goal is to improve validated health indicators such as blood pressure, metabolic risk, body composition, muscle strength, sleep and physical capacity.

Is whole-body MRI necessary in a longevity check-up?

Generally not. Whole-body MRI is not a standard screening method with demonstrated benefit for everyone who is low-risk and asymptomatic. Incidental findings can lead to unnecessary investigations and anxiety. Imaging should be targeted according to personal risk, symptoms or examination findings.

References

  1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney International. 2024;105(Suppl 4S)–S314. KDIGO 2024 CKD Guideline

  2. American Diabetes Association Professional Practice Committee. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1). doi: 10.2337/dc26-S002

  3. Mach F, Baigent C, Catapano AL, et al. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias. European Heart Journal. 2025;46(42):4359–4378. doi: 10.1093/eurheartj/ehaf190

  4. SCORE2 Working Group and ESC Cardiovascular Risk Collaboration. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. European Heart Journal. 2021;42(25):2439–2454. doi: 10.1093/eurheartj/ehab309

  5. US Preventive Services Task Force. Screening for Osteoporosis to Prevent Fractures: US Preventive Services Task Force Recommendation Statement. JAMA. 2025. USPSTF Recommendation

  6. Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age and Ageing. 2019;48(1):16–31. doi: 10.1093/ageing/afy169

  7. Lang JJ, Prince SA, Merucci K, et al. Cardiorespiratory fitness is a strong and consistent predictor of morbidity and mortality among adults. British Journal of Sports Medicine. 2024;58:556–566. doi: 10.1136/bjsports-2023-107849

  8. Republic of Türkiye Ministry of Health. National Cancer Screening Programme: 1–7 April 2026 National Cancer Week. Official information

  9. Chen Q, Dwaraka VB, Carreras-Gallo N, et al. OMICmAge quantifies biological age by integrating multi-omics with electronic medical records. Nature Aging. 2026;6:722–737. doi: 10.1038/s43587-026-01073-7

  10. Belsky DW, Caspi A, Corcoran DL, et al. DunedinPACE, a DNA methylation biomarker of the pace of aging. eLife. 2022;11. doi: 10.7554/eLife.73420

  11. Sehgal R, Markov Y, Qin C, et al. Systems Age: a single blood methylation test to quantify aging heterogeneity across 11 physiological systems. Nature Aging. 2025;5(9):1880–1896. doi: 10.1038/s43587-025-00958-3

  12. Lu AT, Seeboth A, Tsai PC, et al. DNA methylation-based estimator of telomere length. Aging. 2019;11(16):5895–5923. doi: 10.18632/aging.102173

  13. Ye Q, Apsley AT, Etzel L, et al. Telomere length and chronological age across the human lifespan: A systematic review and meta-analysis of 414 study samples including 743,019 individuals. Ageing Research Reviews. 2023;90:102031. doi: 10.1016/j.arr.2023.102031

  14. Moqri M, Herzog C, Poganik JR, et al. Validation of biomarkers of aging. Nature Medicine. 2024;30:360–372. doi: 10.1038/s41591-023-02784-9

  15. World Health Organization Regional Office for Europe. Screening programmes: a short guide. Increase effectiveness, maximize benefits and minimize harm. Copenhagen: WHO Regional Office for Europe; 2020. WHO publication